SARACENO, ROSITA
 Distribuzione geografica
Continente #
NA - Nord America 15.887
AS - Asia 1.687
EU - Europa 1.687
SA - Sud America 250
Continente sconosciuto - Info sul continente non disponibili 246
AF - Africa 37
OC - Oceania 18
Totale 19.812
Nazione #
US - Stati Uniti d'America 15.805
SG - Singapore 619
CN - Cina 529
IT - Italia 250
DE - Germania 230
RU - Federazione Russa 218
UA - Ucraina 213
BR - Brasile 188
FR - Francia 151
HK - Hong Kong 141
IE - Irlanda 135
SE - Svezia 123
GB - Regno Unito 116
VN - Vietnam 103
FI - Finlandia 76
PL - Polonia 64
IN - India 52
KR - Corea 52
BD - Bangladesh 45
CA - Canada 44
JP - Giappone 39
CO - Colombia 23
AR - Argentina 18
AU - Australia 17
ES - Italia 17
AE - Emirati Arabi Uniti 13
NL - Olanda 13
EG - Egitto 12
PH - Filippine 12
SK - Slovacchia (Repubblica Slovacca) 12
TR - Turchia 10
ZA - Sudafrica 10
CH - Svizzera 9
KG - Kirghizistan 9
MX - Messico 9
RO - Romania 9
CR - Costa Rica 8
GR - Grecia 8
IR - Iran 8
PY - Paraguay 8
BE - Belgio 7
PK - Pakistan 7
AT - Austria 6
IQ - Iraq 6
JM - Giamaica 6
MA - Marocco 6
RS - Serbia 6
UZ - Uzbekistan 6
DK - Danimarca 5
EC - Ecuador 5
LV - Lettonia 5
NI - Nicaragua 5
TW - Taiwan 5
CZ - Repubblica Ceca 4
ID - Indonesia 4
LT - Lituania 4
MY - Malesia 4
PT - Portogallo 4
CL - Cile 3
EU - Europa 3
HN - Honduras 3
IL - Israele 3
OM - Oman 3
SA - Arabia Saudita 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BH - Bahrain 2
CW - ???statistics.table.value.countryCode.CW??? 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
NG - Nigeria 2
PE - Perù 2
PS - Palestinian Territory 2
SN - Senegal 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
VE - Venezuela 2
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
JO - Giordania 1
KH - Cambogia 1
KY - Cayman, isole 1
LB - Libano 1
MM - Myanmar 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SC - Seychelles 1
SV - El Salvador 1
UY - Uruguay 1
Totale 19.573
Città #
Woodbridge 4.102
Houston 3.742
Wilmington 3.346
Ashburn 490
Fairfield 454
Singapore 390
Ann Arbor 348
Chandler 320
San Jose 225
Jacksonville 185
Beijing 167
Cambridge 166
Seattle 161
New York 142
Dublin 135
Hong Kong 135
Medford 110
Zhengzhou 92
Dearborn 90
Rome 77
Council Bluffs 76
Dallas 73
Los Angeles 68
The Dalles 66
Santa Clara 59
Lawrence 50
Bar Harbor 36
Kraków 35
Shanghai 34
Tokyo 34
Ho Chi Minh City 33
Moscow 33
Boardman 31
Lauterbourg 31
Buffalo 27
São Paulo 26
Helsinki 25
Menlo Park 25
Hanoi 24
San Diego 21
Denver 19
Orem 19
Redondo Beach 18
London 17
Munich 17
Mülheim 17
San Francisco 17
Warsaw 17
Hefei 16
Norwalk 16
Hangzhou 15
Brooklyn 14
Nanjing 14
Detroit 13
Milan 13
Montreal 13
Redwood City 13
North Bergen 12
Toronto 12
Chennai 11
Chicago 11
Dubai 11
Guangzhou 11
Phoenix 10
Atlanta 9
Da Nang 9
Kunming 9
Stockholm 9
Boston 8
Frankfurt am Main 8
Manchester 8
Naples 8
Paris 8
Columbus 7
Florence 7
Haiphong 7
Madrid 7
Nanchang 7
Palo Alto 7
Philadelphia 7
Redmond 7
San Mateo 7
Verona 7
Brussels 6
Draper 6
Johannesburg 6
Poznan 6
Salt Lake City 6
San José 6
Asunción 5
Bern 5
Bolzano 5
Dhaka 5
Fuzhou 5
Managua 5
Melbourne 5
Mountain View 5
Nuremberg 5
Quezon City 5
Riga 5
Totale 16.267
Nome #
Crusted scabies in a liver transplant patient mimicking rupioid psoriasis 1.403
Atopic dermatitis and dental manifestations 568
Efficacy and safety of infliximab in psoriatic patients over the age of 65 567
Topical lactoferrin can improve stable psoriatic plaque 532
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis 506
-174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers 506
Apremilast for the treatment of psoriasis. 500
Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study 497
Oral lichen planus: therapy and phenotype 492
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 473
Profile of certolizumab and its potential in the treatment of psoriatic arthritis 472
New topical treatments for psoriasis 470
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 469
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 468
Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review 467
Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? 457
Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis 455
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment 451
The significance of the development of antinuclear antibodies during infliximab treatment 443
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. 435
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 429
Oral lichen planus: Novel acquisitions in the pathogenesis and treatment 425
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis 423
Influence and variation of the body mass index in patients treated with etancercept for psoriasis 423
Erysipeloid cutaneous metastasis from bladder carcinoma 419
TNF-α antagonists and nail psoriasis: An open, 24-week, prospective cohort study in adult patients with psoriasis 416
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk 411
Cyclosporine: a novel therapeutic approach for Burning Mouth Syndrome 409
Prevalence and management of panic attacks during infliximab infusion in psoriatic patients 394
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 382
Serum Protein Profile Changes in Psoriatic Patients Undergoing Treatment With Infliximab 378
Does metabolic syndrome influence psoriasis? 375
The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study 372
Tofacitinib for the treatment of moderate-to-severe psoriasis 371
Why 3 mg/kg instead of 5 mg/kg of infliximab should work in psoriatic arthritis? 340
Safety evaluation of apremilast for the treatment of psoriasis 337
Comparison of a novel treatment protocol with oral fluconazole vs probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in the treatment of recurrent vulvovaginal candidiasis 327
Oral lichen planus: Therapy and phenotype 235
A European perspective on the challenges of managing psoriasis 230
308 nm monochromatic excimer light in the treatment of psoriasis 227
Different applications of monochromatic excimer light in skin diseases 208
Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides 187
Treatment of folliculitis with monochromatic excimer light (308 nm). 180
Aphthous, coeliac disease and other dental disorders in childhood 178
Type III juvenile pityriasis rubra pilaris: A successful treatment with infliximab [12] 164
Randomized, within-patient, clinical trial comparing fluorine-synthetic fiber socks with standard cotton socks in improving plantar pustulosis 164
Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab. 162
Nanomedicine in dermatology: Benefits and emerging applications 156
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 135
Clinical severity instruments 135
Keratosis punctata palmoplantaris and malignancies: case report 113
Apheresis in the treatment of recalcitrant atopic dermatitis: Case series and review of the literature 76
Totale 19.812
Categoria #
all - tutte 45.672
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.672


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022401 0 0 0 34 14 54 23 21 40 56 28 131
2022/2023815 70 63 37 119 87 153 56 48 98 11 39 34
2023/2024345 34 8 37 18 26 104 21 13 2 7 10 65
2024/2025980 47 193 106 77 34 58 102 36 74 96 98 59
2025/20261.918 166 95 239 184 196 67 261 196 205 149 92 68
2026/20271.061 113 200 449 299 0 0 0 0 0 0 0 0
Totale 19.812